-- 根據週二提交給澳洲證券交易所的文件顯示，Entropy Neurodynamics（ASX：ENP）已根據其TRP-8802（口服裸蓋菇素）治療難治性腸躁症（IBS）患者的2a期臨床研究結果，向美國提交了一項臨時專利申請。 此次申請是對其現有國際專利申請的補充，該國際專利申請涉及迷幻劑輔助治療腸腦交互作用障礙，已於2024年1月3日根據《專利合作條約》提交。 研究結果顯示，難治性IBS患者的緩解率高達75%，該公司指出，這是迄今為止IBS藥物研發中報告最強的臨床訊號。 週二，該公司股價下跌5%。
Related Articles
Research
Research Alert: Ab Inbev Q1 Tops Estimates; Corona Momentum, Volume Recovery Support Outlook
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ABI reported Q1 2026 organic revenue growth of 5.8%, beating consensus of 3.0%, supported by revenue per hectoliter growth of 4.5% and a volume increase of 0.8% vs. expected decline of 0.5%. Underlying EPS of USD0.97 surpassed consensus of USD0.89 and the prior year's USD0.81, representing the highest Q1 performance in company history. We believe ABI's megabrands momentum, with combined revenues growing 8.2%, led by Corona's 16% growth outside its home market, demonstrates competitive positioning strength with market share gains in 75% of its markets. Management maintained 2026 EBITDA growth guidance of 4-8%, in line with its medium-term outlook and consensus of 5.1%, with capex expected at USD3.5-4.0B. The Beyond Beer segment accelerated with 37% revenue growth, while gross margin expanded 76 bps to 56.6% despite EBITDA margin contracting 15 bps due to increased marketing investments. We remain confident in ABI's growth trajectory given its global portfolio strength and resilient market positioning.
$BUD
Asia
Tyntek Logs About NT$17 Million in Q1 Profit; Shares Rally 10%
Tyntek (TPE:2426) posted a profit attributable to owners of NT$16.6 million, or NT$0.06 per share, for the first quarter, according to a Monday filing with the Taiwan Stock Exchange.Shares jumped 10% in Tuesday's midday trade.Meanwhile, operating revenue stood at NT$545.1 million.The chip manufacturer did not provide comparative year-ago figures.
$TPE:2426
Asia
Ambuja Cements' Consolidated Profit Jumps in Fiscal Q4; Shares Fall 3%
Ambuja Cements' (NSE:AMBUJACEM, BOM:500425) consolidated attributable profit increased to 18.3 billion Indian rupees in the fiscal fourth quarter from 10.3 billion rupees a year ago, according to a filing to the Indian stock exchanges on Monday.Shares of the cement manufacturer were down nearly 3% in Tuesday's trade.Earnings per share during the quarter ended March 31 climbed to 7.37 rupees from 4.16 rupees a year earlier.Revenue from operations in fiscal Q4 also rose year on year to 108.9 billion rupees from 98.9 billion rupees a year earlier.The company's board recommended a final dividend of 2 rupees per share for the financial year ended March 31. The dividend will be paid on or after July 1 to shareholders of record on June 12, the filing said.
$BOM:500425$NSE:AMBUJACEM